Krystal Biotech Q2 2026: VYJUVEK Revenue Reaches $119M as Pipeline Advances
KRYS has more than doubled off its 52-week low of $130.5.
Summary
Krystal Biotech reported Q2 2026 revenue of $119.2M, up 24% YoY, and net income of $54.8M. With $845.6M in cash, the company is advancing multiple pipeline programs, including completed enrollment in the IOLITE Phase 3 study.
Key Events · Earnings and Guidance · KRYS
-
VYJUVEK Revenue Grows 24%
Net product revenue reached $119.2 million in Q2 2026, up from $96.0 million a year ago, driven by launches in Europe and Japan.
-
Net Income Jumps 43%
Net income was $54.8 million, or $1.79 per diluted share, compared to $38.3 million, or $1.29 per share, in Q2 2025.
-
Strong Cash Position
Cash, cash equivalents, and short-term investments totaled $845.6 million as of June 30, 2026, sufficient to fund operations for at least 12 months.
-
Pipeline Milestones
Enrollment completed in the IOLITE Phase 3 study for KB803; EMERALD-1 registrational study for KB801 is enrolling; repeat-dose study for KB407 initiated.
Analysis · KRYS · Life Sciences
Krystal Biotech posted a strong second quarter, with VYJUVEK net revenue climbing 24% year-over-year to $119.2 million, fueled by launches in Europe and Japan. Net income surged 43% to $54.8 million, and the balance sheet remains robust with $845.6 million in cash and short-term investments, providing ample runway. On the pipeline front, enrollment in the IOLITE Phase 3 study for KB803 in DEB ocular complications is now complete, and the EMERALD-1 registrational study for KB801 in neurotrophic keratitis is actively enrolling. A new inventorship lawsuit filed in May 2026 concerning KB407 patents introduces some legal uncertainty, though management considers the claims meritless.
At the time of this filing, KRYS was trading at $315.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $130.50 to $382.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.